Regarding the HIV/AIDS patient in Question 5, a peptidomimetic agent that blocks virus-mediated cleavage of viral structural protein precursors is chosen as a second drug. That drug is
(A) Acyclovir
(B) Amantadine
(C) Ribavirin
(D) Saquinavir
(E) Lamivudine
(F) Fuzeon

Question 5

A 40-year-old man has HIV/AIDS characterized by a low CD4 count and a high viral load. Highly active antiretroviral therapy (HAART) will be initiated. One of the drugs under consideration is a nucleoside analog that inhibits viral reverse transcriptase and is active against both HIV and hepatitis B virus. That drug is
(A) Acyclovir
(B) Amantadine
(C) Ribavirin
(D) Saquinavir
(E) Lamivudine
(F) Fuzeon